Explore top Citizens Financial Group, Inc. preferred stocks, yield comparisons, and expert ratings. Click for more on CFG and ...
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 Earnings Call Transcript November 13, 2025 ...
Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsRick Winningham - CEO & DirectorRhonda Farnum ...
2d
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and ...
Q3 2025 Earnings Call Transcript November 13, 2025Protalix BioTherapeutics, Inc. misses on earnings expectations.
Q3 2025 Earnings Call Transcript November 10, 2025 Red Robin Gourmet Burgers, Inc. misses on earnings expectations. Reported ...
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...
Research and development (R&D) expenses for the three months ended September 30, 2025, were $5.3 million, compared to $6.0 million in the same three-month period of 2024 and a decrease from $6.2 ...
Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA®– Q3 2025 operating profit of €11.0 million– TransCon® ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...
Appointed key leadership to drive (Z)-endoxifen development and evolve pathway to commercialization SEATTLE, /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a ...
Some of the biggest NBA off-court stories of the past 25 years feature hot-button, big-picture themes and others, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback